Zacks Investment Research cut shares of Translate Bio (NASDAQ:TBIO) from a hold rating to a sell rating in a research note issued to investors on Saturday, Zacks.com reports.

According to Zacks, “Translate Bio, Inc. operates as a therapeutics company. It develops transformative medicines for the treatment of diseases caused by protein and gene dysfunction. Translate Bio, Inc. is based in MA, United States. “

A number of other equities analysts have also recently weighed in on the company. HC Wainwright started coverage on Translate Bio in a report on Monday, December 24th. They set a buy rating and a $21.00 price target for the company. ValuEngine cut Translate Bio from a buy rating to a hold rating in a report on Friday, December 21st. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of Buy and an average price target of $22.75.

Shares of NASDAQ:TBIO opened at $11.34 on Friday. The company has a debt-to-equity ratio of 0.83, a current ratio of 10.47 and a quick ratio of 10.47. The firm has a market capitalization of $538.71 million and a price-to-earnings ratio of -3.09. Translate Bio has a 52-week low of $4.81 and a 52-week high of $16.60.

Translate Bio (NASDAQ:TBIO) last released its quarterly earnings results on Thursday, March 21st. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.09. The business had revenue of $1.18 million for the quarter, compared to analysts’ expectations of $0.80 million. As a group, equities analysts expect that Translate Bio will post -1.52 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC grew its holdings in shares of Translate Bio by 139.0% during the 4th quarter. Geode Capital Management LLC now owns 117,432 shares of the company’s stock worth $880,000 after purchasing an additional 68,300 shares during the period. Norges Bank purchased a new position in shares of Translate Bio during the 4th quarter worth $263,000. FMR LLC grew its holdings in shares of Translate Bio by 6.8% during the 4th quarter. FMR LLC now owns 6,771,313 shares of the company’s stock worth $50,785,000 after purchasing an additional 433,952 shares during the period. Two Sigma Investments LP purchased a new position in shares of Translate Bio during the 4th quarter worth $118,000. Finally, Barclays PLC grew its holdings in shares of Translate Bio by 82.8% during the 4th quarter. Barclays PLC now owns 6,710 shares of the company’s stock worth $50,000 after purchasing an additional 3,039 shares during the period. Institutional investors and hedge funds own 59.27% of the company’s stock.

About Translate Bio

Translate Bio, Inc, a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 to treat ornithine transcarbamylase deficiency.

Featured Story: How does a reverse stock split work?

Get a free copy of the Zacks research report on Translate Bio (TBIO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Translate Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Translate Bio and related companies with MarketBeat.com's FREE daily email newsletter.